10X Genomics (TXG) closed at $81.55 on October 29, 2026, down 2.5% from the previous close, on volume of 1,725,186 shares (30-day average 3,639,685).
Data as of October 29, 2026.
10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference
PRNewswire (Tue, 27-Oct 4:05 PM ET)
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
PRNewswire (Tue, 13-Oct 4:05 PM ET)
10x Genomics expands oncology push with Fred Hutch collaboration that extends into blood cancers
Market Chameleon (Wed, 7-Oct 5:59 AM ET)
Market Chameleon (Wed, 7-Oct 5:21 AM ET)
PRNewswire (Wed, 7-Oct 9:01 AM ET)
10x Genomics Introduces Sentira, Targeting Spatial Analysis Cycles Cut from Hours to Minutes
Market Chameleon (Tue, 29-Sep 5:18 AM ET)
PRNewswire (Tue, 29-Sep 9:02 AM ET)
PRNewswire (Tue, 29-Sep 9:00 AM ET)
PRNewswire (Thu, 10-Sep 9:01 AM ET)
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
PRNewswire (Fri, 28-Aug 2:39 PM ET)
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
10X Genomics trades on the NASDAQ stock market under the symbol TXG.
As of October 30, 2026, TXG stock price declined to $68.81 with 2,552,352 million shares trading.
TXG has a beta of 1.15, meaning it tends to be more sensitive to market movements. TXG has a correlation of 0.04 to the broad based SPY ETF.
TXG has a market cap of $8.97 billion. This is considered a Mid Cap stock.
Last quarter 10X Genomics reported $151 million in Revenue and -$.14 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.08.
In the last 3 years, TXG traded as high as $102.81 and as low as $6.78.
The top ETF exchange traded funds that TXG belongs to (by Net Assets): VTI, VB, IWM, ARKG, ARKE.
TXG has outperformed the market in the last year with a return of +433.4%, while the SPY ETF gained +11.0%. In the last 3 month period, TXG beat the market returning +48.6%, while SPY returned +3.8%. However, in the most recent 2 weeks TXG has underperformed the stock market by returning -4.9%, while SPY returned -2.1%.
TXG support price is $76.82 and resistance is $86.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TXG shares will trade within this expected range on the day.
